XML 46 R35.htm IDEA: XBRL DOCUMENT
v3.25.3

Revenue - Schedule of Revenue by Sales Category (Details) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended
--- | --- | ---
Sep. 30, 2025 | Sep. 30, 2024 | Sep. 30, 2025 | Sep. 30, 2024
Segment Reporting Information [Line Items] |  |  |  |
Net sales | $ 11,369 | $ 10,635 | $ 32,869 | $ 30,976
United States |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 4,299 | 4,202 | 12,743 | 11,982
International |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 7,070 | 6,433 | 20,126 | 18,994
Operating Segments |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 11,365 | 10,631 | 32,857 | 30,965
Operating Segments | Established Pharmaceuticals |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 1,511 | 1,406 | 4,154 | 3,926
Operating Segments | Established Pharmaceuticals | Key Emerging Markets |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 1,097 | 994 | 3,121 | 2,910
Operating Segments | Established Pharmaceuticals | Other |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 414 | 412 | 1,033 | 1,016
Operating Segments | Nutritional Products |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 2,153 | 2,066 | 6,511 | 6,284
Operating Segments | Nutritional Products | Pediatric Nutritionals |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 977 | 955 | 3,072 | 3,023
Operating Segments | Nutritional Products | Adult Nutritionals |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 1,176 | 1,111 | 3,439 | 3,261
Operating Segments | Diagnostic Products |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 2,253 | 2,412 | 6,480 | 6,821
Operating Segments | Diagnostic Products | Core Laboratory |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 1,364 | 1,314 | 3,899 | 3,848
Operating Segments | Diagnostic Products | Molecular |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 131 | 128 | 376 | 384
Operating Segments | Diagnostic Products | Point of Care |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 158 | 146 | 448 | 441
Operating Segments | Diagnostic Products | Rapid Diagnostics |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 600 | 824 | 1,757 | 2,148
Operating Segments | Medical Devices |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 5,448 | 4,747 | 15,712 | 13,934
Operating Segments | Medical Devices | Rhythm Management |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 686 | 597 | 1,944 | 1,766
Operating Segments | Medical Devices | Electrophysiology |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 705 | 610 | 2,034 | 1,824
Operating Segments | Medical Devices | Heart Failure |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 366 | 322 | 1,073 | 948
Operating Segments | Medical Devices | Vascular |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 745 | 699 | 2,212 | 2,112
Operating Segments | Medical Devices | Structural Heart |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 635 | 558 | 1,848 | 1,637
Operating Segments | Medical Devices | Neuromodulation |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 254 | 236 | 736 | 705
Operating Segments | Medical Devices | Diabetes Care |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 2,057 | 1,725 | 5,865 | 4,942
Operating Segments | United States | Established Pharmaceuticals |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 0 | 0 | 0 | 0
Operating Segments | United States | Established Pharmaceuticals | Key Emerging Markets |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 0 | 0 | 0 | 0
Operating Segments | United States | Established Pharmaceuticals | Other |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 0 | 0 | 0 | 0
Operating Segments | United States | Nutritional Products |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 888 | 950 | 2,800 | 2,761
Operating Segments | United States | Nutritional Products | Pediatric Nutritionals |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 520 | 568 | 1,695 | 1,646
Operating Segments | United States | Nutritional Products | Adult Nutritionals |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 368 | 382 | 1,105 | 1,115
Operating Segments | United States | Diagnostic Products |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 886 | 1,032 | 2,568 | 2,775
Operating Segments | United States | Diagnostic Products | Core Laboratory |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 366 | 332 | 1,049 | 969
Operating Segments | United States | Diagnostic Products | Molecular |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 36 | 37 | 111 | 112
Operating Segments | United States | Diagnostic Products | Point of Care |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 111 | 103 | 315 | 308
Operating Segments | United States | Diagnostic Products | Rapid Diagnostics |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 373 | 560 | 1,093 | 1,386
Operating Segments | United States | Medical Devices |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 2,521 | 2,216 | 7,363 | 6,435
Operating Segments | United States | Medical Devices | Rhythm Management |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 350 | 288 | 994 | 851
Operating Segments | United States | Medical Devices | Electrophysiology |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 322 | 285 | 943 | 841
Operating Segments | United States | Medical Devices | Heart Failure |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 280 | 252 | 824 | 733
Operating Segments | United States | Medical Devices | Vascular |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 280 | 258 | 831 | 787
Operating Segments | United States | Medical Devices | Structural Heart |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 297 | 270 | 868 | 761
Operating Segments | United States | Medical Devices | Neuromodulation |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 196 | 190 | 565 | 563
Operating Segments | United States | Medical Devices | Diabetes Care |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 796 | 673 | 2,338 | 1,899
Operating Segments | International | Established Pharmaceuticals |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 1,511 | 1,406 | 4,154 | 3,926
Operating Segments | International | Established Pharmaceuticals | Key Emerging Markets |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 1,097 | 994 | 3,121 | 2,910
Operating Segments | International | Established Pharmaceuticals | Other |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 414 | 412 | 1,033 | 1,016
Operating Segments | International | Nutritional Products |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 1,265 | 1,116 | 3,711 | 3,523
Operating Segments | International | Nutritional Products | Pediatric Nutritionals |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 457 | 387 | 1,377 | 1,377
Operating Segments | International | Nutritional Products | Adult Nutritionals |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 808 | 729 | 2,334 | 2,146
Operating Segments | International | Diagnostic Products |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 1,367 | 1,380 | 3,912 | 4,046
Operating Segments | International | Diagnostic Products | Core Laboratory |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 998 | 982 | 2,850 | 2,879
Operating Segments | International | Diagnostic Products | Molecular |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 95 | 91 | 265 | 272
Operating Segments | International | Diagnostic Products | Point of Care |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 47 | 43 | 133 | 133
Operating Segments | International | Diagnostic Products | Rapid Diagnostics |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 227 | 264 | 664 | 762
Operating Segments | International | Medical Devices |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 2,927 | 2,531 | 8,349 | 7,499
Operating Segments | International | Medical Devices | Rhythm Management |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 336 | 309 | 950 | 915
Operating Segments | International | Medical Devices | Electrophysiology |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 383 | 325 | 1,091 | 983
Operating Segments | International | Medical Devices | Heart Failure |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 86 | 70 | 249 | 215
Operating Segments | International | Medical Devices | Vascular |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 465 | 441 | 1,381 | 1,325
Operating Segments | International | Medical Devices | Structural Heart |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 338 | 288 | 980 | 876
Operating Segments | International | Medical Devices | Neuromodulation |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 58 | 46 | 171 | 142
Operating Segments | International | Medical Devices | Diabetes Care |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 1,261 | 1,052 | 3,527 | 3,043
Other |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 4 | 4 | 12 | 11
Other | United States |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | 4 | 4 | 12 | 11
Other | International |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Net sales | $ 0 | $ 0 | $ 0 | $ 0

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 220 -SubTopic 40 -Name Accounting Standards Codification -Section 55 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 220 -SubTopic 40 -Name Accounting Standards Codification -Section 55 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40 Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_SegmentReportingInformationLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=us-gaap_NonUsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=abt_EstablishedPharmaceuticalProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=abt_KeyEmergingMarketsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=abt_OtherEmergingMarketsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=abt_NutritionalProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=abt_PediatricNutritionalsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=abt_AdultNutritionalsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=abt_DiagnosticProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=abt_CoreLaboratoryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=abt_MolecularMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=abt_PointOfCareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=abt_RapidDiagnosticsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=abt_MedicalDevicesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=abt_RhythmManagementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=abt_ElectrophysiologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=abt_HeartFailureMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=abt_VascularMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=abt_StructuralHeartMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=abt_NeuromodulationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsegmentsAxis=abt_DiabetesCareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |